Lundbeck announces positive phase II Proof of Concept results with Lu AG09222 in migraine prevention
· The HOPE trial met its primary endpoint in migraine prevention, demonstrating that patients treated with Lu AG09222 had a statistically significantly greater reduction in number of monthly migraine days (MMDs) from baseline to weeks 1 to 4 of treatment compared to placebo. · Lu AG09222 was well tolerated Valby, Denmark, April 19, 2023 - H. Lundbeck A/S (Lundbeck) announced positive results of the HOPE trial, a clinical proof of concept trial of Lu AG09222 as a potential treatment for the prevention of migraine (NCT05133323). The primary analysis concluded that there was a